Authors: Timothy Okechukwu Umahi (University of Manchester) and Onyeka K. Osuji (University of Manchester – School of Law)
Published: August 25, 2011
Abstract: This article argues that the effective corporate social responsibility (CSR) of multinational pharmaceutical companies in developing countries should reflect context, opportunity, proximity, time and impact in accordance with the social integration and ethical approaches to CSR. It proposes a CSR model expressed as CSR=COPTI SI E, which acknowledges access to medicines as a matter in the global public domain, a public choice problem, and a moral responsibility issue for multinational pharmaceutical companies. This model recognises the globalisation of the principle of humanity in communities of place and communities of interest as highlighted by the Global Economic Ethic Manifesto 2009 as an integral part of the responsibilities of multinational pharmaceutical companies. The article suggests an access to medicines CSR framework for pharmaceutical companies that may include pricing, patents, testing, research and development, joint public private initiative and appropriate use of drugs.
Related Regions and Countries: Nigeria
Keywords: Access to medicines, communities, corporate governance, corporate social responsibility, developing countries, ethical, global economic ethic manifesto, globalisation, public choice, social integration